Clinical trial

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to…

NCT00107952 · Cumberland Pharmaceuticals, Industry · Completed

Key facts

NCT number NCT00107952
Title Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Official title A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus
Acronym ATTAIN1
Lead sponsor Cumberland Pharmaceuticals, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Bacterial Pneumonia
Intervention type Drug
Interventions Telavancin, Vancomycin
Enrollment 761
Start date Feb 1, 2005
Primary completion Jul 1, 2007
Completion Jul 1, 2007
First posted Apr 12, 2005
Last update posted Jan 16, 2019
Countries United States

At a glance

  • 1–9 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies